INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
See full prescribing information for complete boxed warning
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Nuplazid (Acadia)
- INDICATIONS: Hallucinations and delusions associated with Parkinson’s disease psychosis
- CLASS: Antipsychotic, Antipsychotic, atypical
- HALF-LIFE: 57 hours
- FDA APPROVAL DATE: 04/29/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Carbamazepine, Chlorpromazine, Clarithromycin, Disopyramide, Drugs known to prolong the QT interval, Gatifloxacin, Indinavir, Itraconazole, Ketoconazole, Moxifloxacin, Phenytoin, Procainamide, Quinidine, Rifampin, Sotalol, St John's Wort, Strong CYP3A4 inhibitors and inducers, Thioridazine, Ziprasidone - PREGNANCY: No available data to inform drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/22/2024
